374 related articles for article (PubMed ID: 31397221)
1. Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
[TBL] [Abstract][Full Text] [Related]
2. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
3. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
5. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sharmin S; Roos I; Simpson-Yap S; Malpas C; Sánchez MM; Ozakbas S; Horakova D; Havrdova EK; Patti F; Alroughani R; Izquierdo G; Eichau S; Boz C; Zakaria M; Onofrj M; Lugaresi A; Weinstock-Guttman B; Prat A; Girard M; Duquette P; Terzi M; Amato MP; Karabudak R; Grand'Maison F; Khoury SJ; Grammond P; Lechner-Scott J; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Turkoglu R; Altintas A; Maimone D; Kermode A; Shalaby N; Pesch VV; Butler E; Sidhom Y; Gouider R; Mrabet S; Gerlach O; Soysal A; Barnett M; Kuhle J; Hughes S; Sa MJ; Hodgkinson S; Oreja-Guevara C; Ampapa R; Petersen T; Ramo-Tello C; Spitaleri D; McCombe P; Taylor B; Prevost J; Foschi M; Slee M; McGuigan C; Laureys G; Hijfte LV; de Gans K; Solaro C; Oh J; Macdonell R; Aguera-Morales E; Singhal B; Gray O; Garber J; Wijmeersch BV; Simu M; Castillo-Triviño T; Sanchez-Menoyo JL; Khurana D; Al-Asmi A; Al-Harbi T; Deri N; Fragoso Y; Lalive PH; Sinnige LGF; Shaw C; Shuey N; Csepany T; Sempere AP; Moore F; Decoo D; Willekens B; Gobbi C; Massey J; Hardy T; Parratt J; Kalincik T
Brain; 2023 Nov; 146(11):4633-4644. PubMed ID: 37369086
[TBL] [Abstract][Full Text] [Related]
6. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
7. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
8. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
10. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
11. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
12. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
[TBL] [Abstract][Full Text] [Related]
13. Early predictors of conversion to secondary progressive multiple sclerosis.
Barzegar M; Najdaghi S; Afshari-Safavi A; Nehzat N; Mirmosayyeb O; Shaygannejad V
Mult Scler Relat Disord; 2021 Sep; 54():103115. PubMed ID: 34216997
[TBL] [Abstract][Full Text] [Related]
14. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
[TBL] [Abstract][Full Text] [Related]
16. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
Kearney H; Miszkiel KA; Yiannakas MC; Altmann DR; Ciccarelli O; Miller DH
Mult Scler; 2016 Jun; 22(7):910-20. PubMed ID: 26432854
[TBL] [Abstract][Full Text] [Related]
17. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
18. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
19. Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Manouchehrinia A; Zhu F; Piani-Meier D; Lange M; Silva DG; Carruthers R; Glaser A; Kingwell E; Tremlett H; Hillert J
Mult Scler; 2019 Jul; 25(8):1102-1112. PubMed ID: 29911467
[TBL] [Abstract][Full Text] [Related]
20. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
